-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Reiterates Market Outperform on Crinetics Pharmaceuticals, Maintains $95 Price Target

Benzinga·06/11/2026 14:21:25
Listen to the news
Citizens analyst Jonathan Wolleben reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Market Outperform and maintains $95 price target.